Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Capecitabine for Second-Line Biliary Tract Cancer
NCT02720601Phase 2Withdrawn
- Sponsor
- New Mexico Cancer Research Alliance
- Start
- Nov 2015
- Primary completion
- Mar 2018
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and capecitabine in biliary tract cancer (BTC), sponsored by New Mexico Cancer Research Alliance. Primary endpoint: Progression-free survival at 6 months. Planned start Nov 2015; status: withdrawn.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabcapecitabine
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT02720601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720601.